• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Sano Genetics Secures $11.4M to Turbocharge Precision Medicine Research

by Jasmine Pennic 01/22/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Sano Genetics, a software company that is revolutionizing precision medicine research, has secured $11.4M in new funding.

– This latest investment, led by Plural with participation from existing investors MMC Ventures, Episode 1, and Seedcamp, brings the company’s total funding to $22M.

Revolutionizing Precision Medicine Research

Founded by a trio of visionary minds – Patrick Short (CEO), Charlotte Guzzo (COO), and William Jones (CTO) – Sano Genetics is crafting software that’s poised to revolutionize the way we conduct precision medicine research. Their platform seamlessly integrates genetic testing, patient recruitment, and long-term engagement, empowering researchers to:

  • Accelerate enrollment: Finding the right participants for clinical trials is notoriously challenging, especially in the realm of precision medicine. Sano’s platform cuts through the red tape, connecting patients across four countries (UK, US, Australia, and Canada) with relevant studies, up to three times faster than traditional methods.
  • Simplify operations: Gone are the days of clunky, siloed systems. Sano’s platform provides a unified hub for managing all aspects of a clinical trial, from participant communication and genetic testing to result delivery and even genetic counseling.
  • Leverage the power of AI: Sano is actively deploying AI to optimize the trial process, personalize the patient experience, and ultimately, delight its customers.

The Urgency of Innovation in Clinical Research

Clinical trials, the backbone of modern healthcare, are often bogged down by inefficiencies. Recruiting participants can be a monumental task, with only one in five trials meeting their enrollment targets on time. This translates to agonizing delays in bringing potentially life-saving treatments to patients.

The challenge intensifies in precision medicine, where identifying the right patients based on their genetic makeup is crucial. Existing solutions for patient recruitment, genetic testing, and engagement are often sluggish and cumbersome, further inflating the already exorbitant costs of R&D. For instance, the average R&D cost for a new precision oncology drug stands at a staggering $3.53 billion, compared to $4.62 billion for non-precision oncology medicines.

Sano Genetics: Bridging the Gap and Empowering Patients

Sano Genetics is a beacon of hope in this complex landscape. Their platform acts as a digital matchmaker, effortlessly connecting patients with suitable clinical trials and pharmaceutical/biotech companies seeking participants. This not only expedites the research process but also empowers patients to play an active role in shaping the future of medicine.

A Platform Fueling a Generational Shift in Drug Development

Precision medicine represents a paradigm shift in drug development. Clinical trials utilizing genetic data boast a 26% success rate, compared to a meager 10% for traditional trials. Sano Genetics is at the forefront of this revolution, providing the technological backbone for research institutions and companies worldwide to conduct precision medicine trials with greater efficiency and effectiveness.

Their platform has already supported over 20 diverse studies, ranging from rare and ultra-rare diseases affecting newborns to neurodegenerative conditions like ALS and Parkinson’s. This dedication to patient-centric research extends beyond clinical trials. In December 2023, Sano launched Light The Way, a program offering peer support, DNA testing, genetic counseling, and education to families impacted by ALS.

The Future of Precision Medicine is Now

With this new funding boost, Sano Genetics is poised to scale its impact and realize its ambitious vision of accelerating the future of precision medicine. Their focus on leveraging AI, expanding their global reach, and spearheading initiatives like Light The Way demonstrates a deep commitment to not only streamlining research but also empowering patients to take control of their health.

“Precision medicine is transforming how we think about and approach healthcare, and clinical trials are the bedrock of precision drug development. In the past 12 months, we’ve scaled up our capacity to hold three times more trials than the year before and launched our first programme supporting families affected by ALS. I’m so pleased with everything the team has achieved so far and this new funding will help us to integrate LLMs and other AI tools to drive more productivity. This will help us continue our growth trajectory, particularly with the help of visionary investors like Carina Namih, who supported our seed round and is now supporting us again at Plural,” said Patrick Short, co-founder and CEO of Sano Genetics.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Precision Medicine

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |